Today: 19 March 2026
Subscribe
Browse Category

Biotechnology 4 January 2026 - 9 January 2026

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering shares surged 24% to $8.33 premarket after reporting 64% overall 12-month survival in a 34-patient Phase 2a pancreatic cancer trial. The company compared this to a 35% benchmark from standard chemotherapy. Median progression-free survival reached 8.5 months. Immuneering plans a larger data update and to start a Phase 3 trial in mid-2026.
8 January 2026
···
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
···
Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics shares rose 5.6% to $66.75 after an SEC filing revealed a $100 million upfront payment and low single-digit royalties from Roche and Genentech for a patent license covering oral GLP-1 drugs, including CT-996. The agreement does not affect Structure’s lead candidate, aleniglipron. Full contract details will be disclosed in the annual report.
7 January 2026
·
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience Holdings shares jumped 18.3% to $31.99 in midday Nasdaq trading Tuesday, after swinging between $26.60 and $34.40. No new company statements have been posted since its Oct. 31 annual report, which disclosed a DOJ trading probe and “substantial doubt” about its ability to continue as a going concern. About 850,000 shares changed hands.
6 January 2026
··
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences shares surged 17.2% to $17.58 Tuesday on heavy volume, after new data from Arrowhead Pharmaceuticals showed weight loss benefits from RNAi obesity drugs. Wave is developing a similar therapy, WVE-007, targeting the same gene. The company recently raised $402.5 million in a public offering. Investors await further trial results expected in early 2026.
6 January 2026
··
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics shares surged 46% to $2.01 premarket Tuesday after announcing an expanded exclusive collaboration with Medsteer for its CYC-126 depression program. The company aims to start a Phase 2 proof-of-concept study in late 2026, with initial data expected in 2027. Cyclerion flagged “substantial doubt” about its ability to continue as a going concern and said it needs more funding.
6 January 2026
··
Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific shares climbed 2.4% to $606.63 after Evercore ISI raised its price target to $650 and reaffirmed an “outperform” rating. The stock traded between $590 and $608.29 on volume of 1.6 million shares. Peers Danaher, Agilent, and Illumina also advanced. Investors await Thermo Fisher’s fourth-quarter results on Jan. 29 and updates on its planned $9.4 billion Clario acquisition.
5 January 2026
···
1 … 3 4 5 6 7 … 16

Stock Market Today

  • Bluesky raises $100M Series B amid CEO transition and rapid user growth
    March 19, 2026, 4:59 PM EDT. Bluesky, a social network built on the decentralized AT Protocol, announced a $100 million Series B funding round led by Bain Capital Crypto. The round, closed in April 2025 but disclosed recently, follows previous Series A and seed rounds. The funding comes as CEO Jay Graber steps down to become chief innovation officer, aiming to bring in leadership focused on commercial growth. Bluesky's user base has surged from 13 million to over 43 million globally, with its interoperable app ecosystem expanding. Despite crypto-focused investors, Bluesky has not integrated cryptocurrencies or blockchain technology directly, though its decentralized design attracts crypto interest. The new capital will help scale the team and enhance Bluesky's app and developer ecosystem, now comprising about 20 billion public data records and over 1,000 apps built on AT Protocol.
Go toTop